TY  - JOUR
AU  - Knauf, Wolfgang
AU  - Dingeldein, Gerrit
AU  - Schlag, Rudolf
AU  - Welslau, Manfred
AU  - Moehler, Thomas
AU  - Terzer, Tobias
AU  - Walter, Sarah
AU  - Goldschmidt, Hartmut
AU  - Raab, Marc-Steffen
AU  - group, BPV trial
TI  - First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
JO  - European journal of haematology
VL  - 105
IS  - 2
SN  - 1600-0609
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2020-00525
SP  - 116-125
PY  - 2020
N1  - 2020 Aug;105(2):116-125
AB  - The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the 3-drug-combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM).Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of 9 cycles.46 patients were included into the trial with a median age of 76 years. 19 patients had renal impairment at baseline. The ORR was 76.5
LB  - PUB:(DE-HGF)16
C6  - pmid:32155662
DO  - DOI:10.1111/ejh.13409
UR  - https://inrepo02.dkfz.de/record/153915
ER  -